Hyperbaric chamber manufacturer BioBarica has received approval from the United States Food and Drug Administration (FDA) for its hyperbaric oxygen therapy chambers, marking a new expansion opportunity.

A hyperbaric chamber is a medical device in which the patient breathes high concentrations of oxygen through a mask in a pressurised environment at 1.45 ATA. It increases the concentration and availability of oxygen in blood plasma and generates hyperoxia that acts in all the tissues.

Following the approval, the company is starting the team building process in the US and they are looking to add distributors who want to enter the healthcare business, with innovative profiles and ambition to grow professionally.

“The FDA registration is a great satisfaction for us. Our company was born in 2010 and since then we have grown and expanded in Europe, the Middle East, Africa, and Latin America. We finally reached the United States, which is an extremely competitive market with high standards,” said Ivo Teler, BioBarica’s Commercial Director.

“We are very happy with the growth that the company has had in recent years and we feel a great commitment to this new phase. We not only manufacture and distribute high-quality hyperbaric chambers, we also provide medical, commercial, technical, and scientific training, and know-how to efficiently operate a Hyperbaric Oxygenation Unit or treatment centre. This adds a lot of value to our activity,” added Claudio Teler, CEO of BioBarica.

“Our goal is for more physicians to incorporate the Hyperbaric Chamber so patients can benefit from this safe and effective treatment. To do this, we need to continue adding multidisciplinary professionals to collaborate with us in spreading the benefits of Hyperbaric Oxygenation in the United States,” concludes Claudio.